The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.
 
Martin Wermke
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Cellex GmbH; Gemoab; ISA Pharmaceuticals; Macrogenics; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Cellex GmbH; Lilly; Novartis; Pfizer
Research Funding - Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol Myers Squibb; Genzyme; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; Novartis; PeerVoice; Pfizer; Prime Oncology; Roche; Springer; Takeda; touchIME
Research Funding - EMD Serono (Inst); Merck (Inst)
Other Relationship - GRÍFOLS
 
Valentina Gambardella
No Relationships to Disclose
 
Yasutoshi Kuboki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Daniel Morgensztern
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; G1 Therapeutics; Gilead Sciences; PharmaMar; Takeda
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst)
 
Zohra Oum'Hamed
Employment - Boehringer Ingelheim
 
Junxian Geng
Employment - Boehringer Ingelheim; Boehringer Ingelheim (I)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Matus Studeny
Employment - Boehringer Ingelheim
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; Eisai; EMD Serono; G1 Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Novartis; PharmaMar; Roche/Genentech; Takeda; Wells Fargo; Xcovery; Zentalis
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; Eisai (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Turning Point Therapeutics (Inst); United Therapeutics (Inst); WindMIL (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical